{
    "clinical_study": {
        "@rank": "16610", 
        "acronym": "SMC-LCS-II", 
        "arm_group": {
            "arm_group_label": "Lymphoma", 
            "description": "Lymphoma patients"
        }, 
        "biospec_descr": {
            "textblock": "1. Serum\n\n        2. Tissue specimen\n\n        3. DNA from peripheral blood mononuclear cells"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to establish a model which can predict the treatment outcome\n      and the risk of treatment-related morbidity in patients with lymphoma."
        }, 
        "brief_title": "Samsung Medical Center-Lymphoma Cohort Study-II", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphoma", 
        "condition_browse": {
            "mesh_term": "Lymphoma"
        }, 
        "detailed_description": {
            "textblock": "Although the cure rate of lymphoma has been increased due to the development of newer\n      effective drugs, a substantial portion of patients is still suffered from relapse.\n      Furthermore, the treatment-related morbidity is another factor which can make the treatment\n      outcome worse in patients with lymphoma, especially elderly patients. Thus, this study is\n      going to assess factors which may affect the treatment outcome and the risk of\n      treatment-related morbidity.\n\n      1.Biologic factors associated with the aggressiveness of lymphoma\n\n        -  molecular markers in serum, cytogenetic markers 2.Factors associated with the risk of\n           treatment-related morbidity\n\n        -  comorbidity, nutrition status, performance status, quality of life at diagnosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who were diagnosed as lymphoma\n\n          -  Over 19 years old\n\n          -  Patients who agreed the enrollment of study\n\n          -  Informed consent for sampling\n\n        Exclusion Criteria:\n\n        \u2022Patients who do not want to join the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Newly visited lymphoma patients at the Samsung Medical Center"
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01877109", 
            "org_study_id": "2011-11-056"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lymphoma", 
            "Prognosis", 
            "Biomarker", 
            "Quality of life"
        ], 
        "lastchanged_date": "June 10, 2013", 
        "location": {
            "contact": {
                "email": "wskimsmc@skku.edu", 
                "last_name": "Won Seog Kim, MD, PhD", 
                "phone": "82-2-3410-6548"
            }, 
            "contact_backup": {
                "email": "kstwoh@skku.edu", 
                "last_name": "Seok Jin Kim, MD, PhD", 
                "phone": "82-2-3410-1766"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Won Seog Kim, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Seok Jin Kim, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Juhee Cho, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Observation Cohort Study of Malignant Lymphoma Patients", 
        "overall_contact": {
            "email": "wskimsmc@skku.edu", 
            "last_name": "Won Seog Kim, MD, PhD", 
            "phone": "82-2-3410-6548"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Disease and non-disease-related mortality including treatment-related death", 
            "measure": "All cause mortality", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01877109"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Won Seog Kim", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Response to primary and salvage treatment Revised response criteria for lymphoma should be used (J Clin Oncol 2007;25(5):579-586).\nComplete response: disappearance of all evidence of disease Partial response: regression of measurable disease and no new sites Stable disease: failure to attain CR/PR or PD Relapsed disease or Progressive disease: Any new lesion or increase by >=50% of previously involved sites from nadir", 
                "measure": "Treatment response", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Infectious complications and other toxicities", 
                "measure": "Rate of occurrence of toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "2 years from the start of the 1st therapy"
            }, 
            {
                "description": "Change of quality of life", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Biomarkers associated with treatment outcome", 
                "measure": "Biomarker development", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "June 2013"
    }
}